CAS 49763-96-4
:Stiripentol
Description:
Stiripentol is an anticonvulsant medication primarily used in the treatment of epilepsy, particularly in patients with Dravet syndrome, a severe form of epilepsy. It is classified as a benzodioxole derivative and functions by enhancing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits neuronal excitability. Stiripentol is known for its ability to increase the effectiveness of other antiepileptic drugs, particularly clobazam, and is often used in combination therapy. The substance has a relatively low solubility in water, which can affect its bioavailability. Its pharmacokinetics involve hepatic metabolism, and it is primarily excreted through the urine. Common side effects may include sedation, loss of appetite, and gastrointestinal disturbances. Due to its specific therapeutic applications and interactions with other medications, stiripentol is typically prescribed under careful medical supervision. As with any medication, monitoring for efficacy and adverse effects is essential to ensure optimal treatment outcomes for patients with epilepsy.
Formula:C14H18O3
InChI:InChI=1S/C14H18O3/c1-14(2,3)13(15)7-5-10-4-6-11-12(8-10)17-9-16-11/h4-8,13,15H,9H2,1-3H3
InChI key:InChIKey=IBLNKMRFIPWSOY-UHFFFAOYSA-N
SMILES:C(=CC(C(C)(C)C)O)C=1C=C2C(=CC1)OCO2
Synonyms:- (1E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol
- 1-(1,3-Benzodioxol-5-Yl)-4,4-Dimethylpent-1-En-3-Ol
- 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol
- 1-Penten-3-ol, 1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-
- 256-480-9
- 4,4-Dimethyl-1-(3,4-methylenedioxyphenyl)-1-penten-3-ol
- Bcx 2600
- Diacomit
- Stiripentol
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 11 products.
1-(Benzo[d][1,3]Dioxol-5-Yl)-4,4-Dimethylpent-1-En-3-Ol
CAS:1-(Benzo[d][1,3]Dioxol-5-Yl)-4,4-Dimethylpent-1-En-3-OlPurity:99%Molecular weight:234.29g/molStiripentol
CAS:Formula:C14H18O3Purity:≥ 98.0%Color and Shape:White to off-white powder or solidMolecular weight:234.29Stiripentol
CAS:Formula:C14H18O3Purity:>98.0%(GC)Color and Shape:White to Almost white powder to crystalMolecular weight:234.30Stiripentol
CAS:Stiripentol (BCX2600) (STP) is an anticonvulsant agent, which can inhibit N-demethylation of CLB to NCLB mediated by CYP3A4 (noncompetitively) and CYP2C19 (Formula:C14H18O3Purity:99.87% - >99.99%Color and Shape:White SolidMolecular weight:234.29Stiripentol
CAS:Controlled Product<p>Applications An epilepsy drug. It has been used as co-therapy for treatment of epilepsy. It inhibits the enzymes responsible for metabolism of other anti-convulsant agents.<br>References Laurie, D., et al.: J. Neurosci., 12, 4151 (1992), Smith, A., et al.: J. Pharmacol. Exp. Therap., 311, 601 (2004), Trojnar, M., et al.: Pharm. Rep., 57, 154 (2005), Drafts, B., et al.: J. Pharm. Exp. Ther., 318, 1094 (2006), Picton, A., et al.: Brain Res., 1165, 40 (2007),<br></p>Formula:C14H18O3Color and Shape:Light Yellow SolidMolecular weight:234.294,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol
CAS:<p>4,4-Dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol is a drug that has been used in the treatment of Dravet syndrome. This drug is also known as 3,4-methylenedioxyphenylacetone. It is a competitive inhibitor of the enzyme citrate synthase and inhibits the conversion of acetate to citrate. The effect of 4,4-dimethyl-1-[(3,4-methylenedioxy)phenyl]-1-penten-3-ol on sodium citrate concentrations is concentration dependent and results in an increase in plasma sodium concentrations with prolonged administration. Other drugs that are metabolized by the cytochrome P450 system may interact with 4,4-dimethyl-1-[(3,4 methylenedioxy)phenyl]-1 penten 3 ol and lead to increased levels of these drugs in the blood.</p>Formula:C14H18O3Purity:Min. 95%Color and Shape:White PowderMolecular weight:234.29 g/molStiripentol-13C3
CAS:Controlled ProductFormula:C3C11H18O3Color and Shape:NeatMolecular weight:237.269








